1. Home
  2. BEAM vs KYN Comparison

BEAM vs KYN Comparison

Compare BEAM & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • KYN
  • Stock Information
  • Founded
  • BEAM 2017
  • KYN 2004
  • Country
  • BEAM United States
  • KYN United States
  • Employees
  • BEAM N/A
  • KYN N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • KYN Finance/Investors Services
  • Sector
  • BEAM Health Care
  • KYN Finance
  • Exchange
  • BEAM Nasdaq
  • KYN Nasdaq
  • Market Cap
  • BEAM 1.9B
  • KYN 2.1B
  • IPO Year
  • BEAM 2020
  • KYN N/A
  • Fundamental
  • Price
  • BEAM $24.70
  • KYN $13.03
  • Analyst Decision
  • BEAM Buy
  • KYN
  • Analyst Count
  • BEAM 10
  • KYN 0
  • Target Price
  • BEAM $47.67
  • KYN N/A
  • AVG Volume (30 Days)
  • BEAM 1.1M
  • KYN 561.5K
  • Earning Date
  • BEAM 02-25-2025
  • KYN 01-01-0001
  • Dividend Yield
  • BEAM N/A
  • KYN 8.99%
  • EPS Growth
  • BEAM N/A
  • KYN N/A
  • EPS
  • BEAM N/A
  • KYN 0.71
  • Revenue
  • BEAM $349,643,000.00
  • KYN N/A
  • Revenue This Year
  • BEAM N/A
  • KYN N/A
  • Revenue Next Year
  • BEAM $10.82
  • KYN N/A
  • P/E Ratio
  • BEAM N/A
  • KYN $13.79
  • Revenue Growth
  • BEAM 328.73
  • KYN N/A
  • 52 Week Low
  • BEAM $20.84
  • KYN $7.84
  • 52 Week High
  • BEAM $49.50
  • KYN $9.88
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 41.30
  • KYN 58.95
  • Support Level
  • BEAM $24.96
  • KYN $12.02
  • Resistance Level
  • BEAM $29.52
  • KYN $12.51
  • Average True Range (ATR)
  • BEAM 1.64
  • KYN 0.33
  • MACD
  • BEAM -0.51
  • KYN 0.03
  • Stochastic Oscillator
  • BEAM 9.71
  • KYN 99.25

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: